Kantanen Anne-Mari, Reinikainen Matti, Parviainen Ilkka, Kälviäinen Reetta
Department of Neurology, Neurocenter, Epilepsy Center, Kuopio University Hospital, Kuopio, Finland.
Intensive Care Unit, North Karelia Central Hospital, Joensuu, Finland and Faculty of Health Sciences, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland.
Epilepsy Res. 2017 Jul;133:13-21. doi: 10.1016/j.eplepsyres.2017.03.009. Epub 2017 Apr 2.
Refractory status epilepticus (RSE) is a neurological emergency with significant morbidity and mortality. We aimed to analyze the long-term outcome of intensive care unit (ICU)-treated RSE and super-refractory status epilepticus (SRSE) patients in a population based cohort.
A retrospective study of ICU- and anesthesia-treated RSE patients in Kuopio University Hospital's (KUH) special responsibility area hospitals in the central and eastern part of Finland from Jan. 1, 2010 to Dec. 31, 2012 was conducted. KUH's catchment area consists of five hospitals-one university hospital and four central hospitals-and covers a population of 840 000. We included all consecutive adult (16 years or older) RSE patients admitted in the participating ICUs during the 3-year period and excluded patients with postanoxic etiologies. We used a modified Rankin Scale (mRS) as a long-term (1-year) outcome measure: good (mRS 0-3, recovered to baseline function) or poor (mRS 4-6, major functional deficit or death).
We identified 75 patients with ICU- and anesthesia-treated RSE, corresponding to an annual incidence of 3.0 (95% confidence interval (CI) 2.4-3.8). 21% of the patients were classified as SRSE, with the annual incidence being 0.6/100 000 (95% CI 0.4-1.0). For RSE, the ICU mortality was 0%, hospital mortality was 7% (95% CI 1.2%-12.8%) (n=5), and one-year mortality was 23% (CI 95% 13.4%-32.5%) (n=17). 48% (n=36) of RSE patients recovered to baseline, and 29% (n=22) showed neurological deficit at 1year. Poor outcome (mRS 4-6) was recorded for 52% (n=39) of the patients. Older age was associated with poorer outcome at 1year (p=0.03). For SRSE, hospital mortality was 6% (n=1) and 1-year mortality was 19% (n=3) (95%CI 0%-38.2%).
During 1-year follow-up, nearly 50% of the ICU-treated RSE patients recovered to baseline function, whereas 30% showed new functional defects and 20% died. SRSE does not have a necessarily poorer outcome. The outcome is worse in older patients and in patients with progressive or fatal etiologies. SE should be treated with generalized anesthesia only in refractory cases after failure of adequately used first- and second-line antiepileptic drugs.
难治性癫痫持续状态(RSE)是一种具有显著发病率和死亡率的神经系统急症。我们旨在分析基于人群队列中接受重症监护病房(ICU)治疗的RSE和超级难治性癫痫持续状态(SRSE)患者的长期预后。
对2010年1月1日至2012年12月31日期间在芬兰中部和东部地区库奥皮奥大学医院(KUH)的特殊责任区医院接受ICU和麻醉治疗的RSE患者进行了一项回顾性研究。KUH的服务区域包括五家医院——一家大学医院和四家中心医院——覆盖人口84万。我们纳入了在3年期间入住参与研究的ICU的所有连续成年(16岁及以上)RSE患者,并排除了缺氧后病因的患者。我们使用改良Rankin量表(mRS)作为长期(1年)预后指标:良好(mRS 0 - 3,恢复到基线功能)或不良(mRS 4 - 6,严重功能缺陷或死亡)。
我们确定了75例接受ICU和麻醉治疗的RSE患者,年发病率为3.0(95%置信区间(CI)2.4 - 3.8)。21%的患者被归类为SRSE,年发病率为0.6/10万(95% CI 0.4 - 1.0)。对于RSE,ICU死亡率为0%,医院死亡率为7%(95% CI 1.2% - 12.8%)(n = 5),1年死亡率为23%(CI 95% 13.4% - 32.5%)(n = 17)。48%(n = 36)的RSE患者恢复到基线,29%(n = 22)在1年时出现神经功能缺损。52%(n = 39)的患者预后不良(mRS 4 - 6)。年龄较大与1年时较差的预后相关(p = 0.03)。对于SRSE,医院死亡率为6%(n = 1),1年死亡率为19%(n = 3)(95%CI 0% - 38.2%)。
在1年的随访中,近50%接受ICU治疗的RSE患者恢复到基线功能,而30%出现新的功能缺陷,20%死亡。SRSE的预后不一定更差。老年患者以及病因进展或致命的患者预后更差。仅在充分使用一线和二线抗癫痫药物失败后的难治性病例中,才应使用全身麻醉治疗癫痫持续状态。